Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Myriad Genetics, Inc.    MYGN

MYRIAD GENETICS, INC.

(MYGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Myriad Submits sPMA for BRACAnalysis CDx Test

share with twitter share with LinkedIn share with facebook
share via e-mail
01/21/2020 | 07:44am EST

By Michael Dabaie

Myriad Genetics said it submitted a supplementary premarket approval application to the U.S. Food and Drug Administration.

The sPMA is for the company's BRACAnalysis CDx test as a companion diagnostic to AstraZeneca and Merck & Co.'s (MRK) Lynparza for men with metastatic castration-resistant prostate cancer.

AstraZeneca and Merck said Tuesday the supplemental New Drug Application for Lynparza was been accepted and granted priority review by the FDA.

Myriad said the filing for BRACAnalysis CDx is based on the positive clinical results from the PROfound study.

Write to Michael Dabaie at michael.dabaie@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.36% 7677 Delayed Quote.-0.43%
MERCK AND COMPANY 0.60% 82.49 Delayed Quote.-9.30%
MERCK KGAA 0.61% 123.4 Delayed Quote.16.52%
MRK HOLDINGS INC. 0.00% 212 End-of-day quote.-1.40%
MYRIAD GENETICS, INC. -0.50% 19.89 Delayed Quote.-26.96%
PROCTER & GAMBLE COMPANY 0.91% 126.58 Delayed Quote.1.35%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MYRIAD GENETICS, INC.
02/14New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Pro..
GL
02/12Myriad Genetics to Present at the SVB Leerink Global Healthcare Conference
GL
02/11Myriad Submits sPMA for myChoice® CDx with Lynparza® in First-Line Maintenanc..
GL
02/07THE LAW OFFICES OF FRANK R. CRUZ : Announces Investigation on Behalf of Myriad G..
BU
02/07MYRIAD GENETICS : Results of Operations and Financial Condition, Regulation FD D..
AQ
02/07MYRIAD GENETICS : Management's Discussion and Analysis of Financial Condition an..
AQ
02/06MYRIAD : Fiscal 2Q Earnings Snapshot
AQ
02/06MYRIAD GENETICS INC : Change in Directors or Principal Officers, Financial State..
AQ
02/06MYRIAD GENETICS INC : Results of Operations and Financial Condition, Regulation ..
AQ
02/06Myriad Genetics Reports Fiscal Second-Quarter 2020 Financial Results
GL
More news
Financials (USD)
Sales 2020 737 M
EBIT 2020 39,5 M
Net income 2020 -62,6 M
Debt 2020 14,7 M
Yield 2020 -
P/E ratio 2020 -23,8x
P/E ratio 2021 -63,5x
EV / Sales2020 2,03x
EV / Sales2021 1,81x
Capitalization 1 483 M
Chart MYRIAD GENETICS, INC.
Duration : Period :
Myriad Genetics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MYRIAD GENETICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 21,30  $
Last Close Price 19,89  $
Spread / Highest target 81,0%
Spread / Average Target 7,09%
Spread / Lowest Target -29,6%
EPS Revisions
Managers
NameTitle
Mark C. Capone President, Chief Executive Officer & Director
John Tannahill Henderson Chairman
Gary A. King Executive Vice President-International Operations
R. Bryan Riggsbee CFO, Treasurer, Chief Accounting Officer & EVP
Robert Gardner Harrison Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
MYRIAD GENETICS, INC.-26.96%1 483
BIOMÉRIEUX19.91%12 127
10X GENOMICS, INC.12.05%8 217
AUTOBIO DIAGNOSTICS CO., LTD.22.35%7 230
DIASORIN S.P.A.1.82%6 931
GUANGZHOU WONDFO BIOTECH CO LTD--.--%2 940